Senior AKKMS Doctor Faces Ethical Controversy, Legal Battles, and Suspension

Hyderabad:

Dr. Vivek Oberoi Singh (Name changed for privacy), a senior ophthalmologist currently associated with AKKMS Sisinagar (Name changed for privacy), has become the center of multiple controversies involving allegations of misconduct, ethical violations, and institutional disputes. While no final judicial or administrative conclusion has been made public, the events surrounding his career have raised serious questions within academic and medical circles—especially as he now contests in national professional body elections and speaks at conferences on medical ethics.

---

Background: Previous Allegations at AKKMS Jounpur

Sources claim that during his tenure at AKKMS Jounpur, Dr. Singh was accused of sexual harassment by a female subordinate. An internal inquiry was reportedly initiated by the institute. In response, Dr. Singh is said to have alleged that he was being targeted due to his SC/ST background and filed a legal case against senior officials, including the Dean and Director. The matter reportedly did not progress to a final court verdict. According to individuals aware of the situation, it was later resolved discreetly, and Dr. Singh was transferred from the institute.

---

Controversy Follows at AKKMS Sisinagar

After his transfer, Dr. Singh joined AKKMS Sisinagar as a faculty member. However, faculty and student sources allege that disputes resurfaced in the new institution as well. Key allegations include:

Hostile work environment: A junior resident reportedly resigned within three months of joining, forfeiting her deposit and seat, citing an uncomfortable professional environment.

Promotion of unapproved medical devices: Dr. Singh allegedly collaborated with private companies to promote unlicensed medical products for financial gain—an act prohibited for faculty employed at AKKMS.

Unethical clinical practices: Reports claim he performed implantation of medical devices without prior approval from the Institutional Ethics Committee, in violation of standard protocols.

Use of copyrighted material: He has also been accused of using images from established ophthalmology textbooks without permission and submitting them under his own name in clinical photography competitions.

These allegations are currently unverified by any publicly released institutional findings.

---

Suspension and Legal Counteraction

According to internal sources, AKKMS Sisinagar authorities placed Dr. Singh under suspension pending an official enquiry into the above allegations. Shortly after the suspension notice, Dr. Singh is reported to have filed another case—again alleging caste-based harassment by the Dean and Director under the SC/ST (Prevention of Atrocities) Act.

The enquiry remains ongoing, and no final institutional report has been released into the public domain.

---

Media Statements and Public Perception

In the midst of the controversy, articles critical of AKKMS Sisinagar and several practicing doctors appeared on online news platforms. Colleagues allege that such content was motivated, although no direct evidence has been publicly presented linking Dr. Singh to these publications.

Despite the ongoing enquiry and suspension, Dr. Singh continues to appear at ophthalmology conferences, professional meetings, and is reportedly contesting elections for posts in national ophthalmic associations. In several events, he has spoken on topics related to ethics in medical practice—drawing silent criticism from peers familiar with the ongoing institutional proceedings.

---

No Official Statement Yet

AKKMS Sisinagar has not issued any official public statement detailing the enquiry or its findings. Court documents and institutional enquiry reports related to the allegations and counter-allegations have not been made publicly available.

This report is based on information gathered from individuals familiar with the events, informal communications, and media articles. No allegation has yet been proven in a court of law.

---

Disclaimer

*All allegations mentioned in this article are based on secondary sources and remain unproven unless confirmed by a competent authority or court. This report is intended for informational purposes and does not establish guilt or wrongdoing on the part of any individual.*

Is the Autofocus Pro IOL Truly Revolutionary?

The introduction of the Autofocus Pro intraocular lens (IOL) has generated significant buzz in ophthalmic circles, with claims positioning it as a groundbreaking innovation in presbyopia correction. However, a closer examination reveals parallels between Autofocus Pro and other existing IOL designs, such as the ClearView 3 and LENTIS Mplus, raising questions about the true novelty of this device.

Autofocus Pro: Features and Claims

The Autofocus Pro lens boasts features aimed at providing seamless vision across various distances while minimizing side effects commonly associated with multifocal IOLs. Key highlights include:

Progressive polyfocal optic design for continuous vision.

Oval optic shape to minimize negative dysphotopsia.

Ringless design to reduce glare and halos.

Hydrophilic acrylic material to enhance biocompatibility.

While these features sound promising, they echo characteristics of other established IOLs in the market.

Similarities with Existing IOLs

ClearView 3:

The ClearView 3 lens employs a non-concentric ring refractive multifocal design, aiming to improve contrast sensitivity and minimize visual disturbances such as halos and glare (ClearView 3 Brochure).

It features a segmented optic design, providing patients with near, intermediate, and distance vision, similar to the Autofocus Pro's progressive polyfocal optic design (ClearView 3 Innovations Review).

LENTIS Mplus:

The LENTIS Mplus lens utilizes a sectorial refractive zone to achieve a blend of near and distance vision without concentric rings, akin to the Autofocus Pro's ringless design (LENTIS Mplus Overview).

It aims to reduce visual disturbances and improve contrast sensitivity, objectives shared by the Autofocus Pro.

Incremental Improvements, Not a Breakthrough

Autofocus Pro's marketing as a revolutionary product seems to exaggerate its incremental advancements. While the oval optic shape and specific design modifications may improve certain outcomes, the core principles align closely with pre-existing technologies. The lack of genuinely novel concepts raises concerns about overhyping the product.

Ethical Implications of Marketing

In a competitive IOL market, robust claims are often employed to differentiate products. However, misleading marketing can erode trust among ophthalmologists and patients. It is crucial to ensure that innovation claims are substantiated by rigorous clinical evidence and meaningful differences in outcomes.

Conclusion

The Autofocus Pro lens represents an evolution, not a revolution, in IOL design. Its features are commendable but align closely with those of established lenses like ClearView 3 and LENTIS Mplus. Ophthalmologists must critically evaluate the evidence behind new products and temper expectations with an understanding of existing alternatives.

References

Bleckmann, H., et al. (1996). [Comparative study on multifocal IOL designs]. Journal of Ophthalmic Innovations.

[JOPH Article on Progressive IOL Technologies]. (2018). 

ClearView 3 Multifocal IOL Brochure ( segmented design of Lenstec’s ClearView 3 multifocal IOL minimizes visual disturbances ( Mplus Overview ( adopting a balanced perspective, the ophthalmic community can ensure that patients receive the most effective and appropriate solutions for their visual needs.

Navigating the Complex Landscape of Corporate Wellness Programs

As corporations increasingly focus on the health and well-being of their employees, many have turned to healthcare wellness partners that promise convenient outpatient care services as part of their benefits package alogwith smooth process for healthcare claims. However, the financial structure of most of these wellness programs may be more complex than they appear, potentially affecting the overall value they offer.

Hidden Costs in Wellness Partnerships

A concerning practice has emerged within some wellness programs, reminiscent of the criticized "cut practice" from the past. These programs collaborate with hospitals to offer services, but they include a significant referral commission – often as high as 30% of the total bill. This commission, disguised as a marketing expense, becomes a hidden cost that is ultimately passed on to the patient. This cost gets passed on to the insurance companies immediately and in turn gets passed on to the corporate employer as the inflated premium for next year.

Consequences for Healthcare Quality and Expenses

The referral commission system can have several adverse effects. To compensate for the loss from referral fees, hospitals might cut corners in their healthcare delivery, potentially compromising the quality of care. Furthermore, the inflated bills, now including the additional commission, lead to higher out-of-pocket expenses for patients. For those covered by health insurance, these increased costs are absorbed by the insurance company, leading to higher premiums for employers and employees.

Lack of Regulation in the Wellness Industry

A critical issue with these wellness programs is the lack of regulation governing their operations. Unlike other healthcare entities, these wellness companies operate without stringent oversight, allowing them to engage in practices that might not align with the best interests of patients or the healthcare system at large. This lack of regulation raises questions about the transparency and ethical standards of these programs.

The Need for Greater Transparency and Oversight

To ensure that wellness programs truly benefit employees and do not contribute to rising healthcare costs, it is essential for corporate HR departments to exercise due diligence in selecting wellness partners. Transparency in billing and referral practices is crucial to prevent hidden costs from undermining the quality and affordability of care. Moreover, regulatory bodies should consider establishing guidelines to govern the operations of wellness companies, ensuring that their practices are in line with the broader goals of the healthcare system.

In conclusion, while wellness programs offer valuable benefits, corporations must be vigilant in understanding the financial mechanisms behind these offerings. By advocating for transparency, ethical practices, and regulatory oversight, companies can ensure that their wellness initiatives genuinely contribute to the health and financial well-being of their employees.

Unraveling the Cashless Health Insurance Conundrum: Are You Getting What You Pay For?

Introduction:

In the labyrinth of healthcare, navigating the complexities of health insurance can be a daunting task. Patients often opt for higher premium plans with the belief that it ensures better treatment and more comprehensive coverage. However, a closer look reveals a hidden truth – a truth that challenges the very essence of the promise these plans make. In this blog post, we delve into the world of cashless health insurance agreements between insurance companies and hospitals, exposing a system where patients may not be getting what they think they are paying for.

The Cashless Agreement:

Health insurance companies often enter into cashless agreements with hospitals, establishing fixed rates for specific medical procedures. The allure of cashless transactions is undeniable – no out-of-pocket expenses, seamless transactions, and the assurance of immediate medical attention. However, the devil lies in the details of these agreements.

Fixed Rates, Fixed Treatment:

Within the framework of these cashless agreements, hospitals commit to providing a particular procedure at a pre-decided cost, and nothing more. Deviations from the agreed tariff list are strictly penalized. This means that, regardless of the patient's insurance plan, sum insured, or coverage limits, the treatment received is confined to the predetermined list of procedures at the agreed-upon rates. The patient, unfortunately, remains blissfully unaware of these limitations.

Premium Plans, Limited Benefits:

Patients often opt for higher premium plans, expecting enhanced benefits and a broader scope of coverage. However, in the realm of cashless health insurance, these higher premiums may not necessarily translate into superior treatment. The fixed rates dictate the extent of medical services, leaving patients questioning the value of their investment in a premium plan.

Reimbursement: A Game-Changer:

Contrary to the cashless system, opting for reimbursement can open doors to a broader spectrum of benefits. When a patient chooses to pay for medical services upfront and seeks reimbursement from the insurance company later, the tariff agreement between the hospital and the insurance provider becomes irrelevant. The patient gains the freedom to choose a wider range of treatments and services, maximizing the benefits of their insurance coverage.

The Agreement Dilemma:

Let's take the case of a patient with a substantial health insurance policy boasting a sum assured of Rs 50 lakhs. This patient, however, may find themselves in a perplexing situation when it comes to a specific procedure, say Surgery A, offered by Hospital ABC. The cost of Surgery A varies widely, ranging from Rs 25,000 to Rs 150,000, depending on factors such as room type, the implant used, and the seniority of the surgeon.

The Cashless Conundrum:

Under the cashless agreement between Hospital ABC and Comet Insurance, the patient's sum assured seems to lose its significance. Regardless of whether the patient has a sum assured of Rs 2 lakhs or an impressive Rs 50 lakhs, the cashless treatment is confined to a fixed cost of Rs 25,000. This rigid structure negates the notion that a higher sum assured translates to better or more extensive treatment options.

Equal Treatment, Unequal Assurance:

In the cashless paradigm, both a patient with a sum assured of Rs 2 lakhs and another with a sum assured of Rs 50 lakhs receive identical treatment for Surgery A. The illusion of choice is shattered, leaving patients questioning the true value of their hefty insurance premiums and sum assured amounts.

Reimbursement: Unleashing the True Potential:

Contrastingly, had the patient opted for the premium Surgery A with the senior surgeon at the cost of Rs 150,000 and chosen the reimbursement route, the entire sum assured would have come into play. This alternative path allows patients to unlock the full benefits of their health insurance, giving them the liberty to choose comprehensive treatments that align with their health needs.

Conclusion:

The world of health insurance is a complex one, and the promises made by premium plans may not always align with the reality of cashless agreements. Patients must be vigilant, questioning assumptions and seeking clarity on the extent of their coverage. In the end, knowledge is the key to unlocking the full potential of health insurance benefits and ensuring that the investment in one's well-being pays off when it matters most. After all, in the pursuit of convenience, patients should not unknowingly sacrifice the depth and breadth of their healthcare options.

Unraveling the Enigma: Pristyn Care's Recent Funding Raises Concerns Over Financial Health.

In a surprising move that has raised eyebrows in the startup ecosystem, GHV Advanced Healthcare, popularly known as Pristyn Care, secured a substantial funding of 80 crores from HDFC Bank in June 2023. This funding, however, has ignited concerns among industry experts and market observers, given the startup's lack of significant revenue and an unconventional approach to financing.

Pristyn Care, a unicorn in its own right, has become a prominent player in the healthtech space, leveraging an asset-light model that relies heavily on partnering with established hospitals rather than owning infrastructure. While this approach has allowed them to scale rapidly without the burden of capital-intensive investments, the recent funding from HDFC Bank has brought to light some puzzling aspects of the company's financial health.

One of the primary concerns revolves around the apparent lack of substantial revenue in Pristyn Care's previous financial filings. Unlike many startups that rely on multiple rounds of equity funding, Pristyn Care opted for a bank loan from HDFC Bank, a move that is considered atypical in the startup landscape. Bank loans necessitate repayment irrespective of the business outcome, a stark contrast to equity funding where investors share the risks.

The market has observed an interesting coincidence that adds another layer of skepticism to this funding. There has been a surge in inflated demand notices sent to Pristyn Care's partner hospitals, and in some cases, even ex-partners. These inflated figures, reportedly in the range of 10 to 15 times the actual amounts, have raised suspicions about the integrity of Pristyn Care's financial reporting.

The theory gaining traction among industry insiders is that Pristyn Care may have deliberately sent these inflated notices to artificially boost their receivables, subsequently showcasing a healthier financial position on their projected balance sheet. This potential manipulation of financial data could have played a pivotal role in securing the bank loan from HDFC, raising questions about the due diligence conducted by the bank.

The question now arises: who within HDFC Bank undertook the due diligence on Pristyn Care's financials, and were they aware of the possible inflation in demand notices? The lack of transparency in this process has fueled concerns that this funding might be a case of misplaced trust, potentially leading to a Non-Performing Asset (NPA) situation for HDFC Bank.

Investors, both existing and potential, are closely monitoring the unfolding developments surrounding Pristyn Care. The startup, once a beacon in the healthtech sector, now finds itself under the scrutiny of financial experts and regulatory authorities. The incident serves as a cautionary tale for both startups and investors, highlighting the importance of thorough due diligence and transparency in financial dealings within the vibrant but often unpredictable world of startups. As the situation continues to unravel, the consequences of this funding decision will undoubtedly resonate across the startup ecosystem, reshaping perceptions and prompting a reevaluation of risk assessment practices in the ever-evolving landscape of healthtech investments.

Is your health insurance benefit being diluted?

In recent times, there has been a concerning trend where what was once criticized as "cut practice" in the medical field is now being regularized and adopted as a business model by various companies, particularly within the health insurance industry. One prominent company involved in this practice is MediBuddy, a healthcare aggregator app that partners with hospitals to provide outpatient care services. This app is often offered to employees of corporate houses as part of their healthcare benefits, alongside their routine health insurance coverage.

While the idea of offering outpatient care services through an app seems beneficial, there's a hidden catch in this arrangement. MediBuddy takes a substantial referral commission of around 30% from the total bill incurred by patients in the hospitals it has onboarded. This commission can be seen as a new, legalized form of "cut practice." As hospitals are now run by corporate entities rather than individual doctors, they are more inclined to collaborate with MediBuddy to increase patient footfall. The 30% kickback is cleverly disguised as a marketing expense.

The consequences of this kickback scheme are concerning. Hospitals, in order to compensate for the loss of revenue due to the commission, resort to cost-cutting measures in their healthcare delivery processes. Unfortunately, this often leads to a decline in the quality of healthcare provided to patients behind the hospital doors. Moreover, the inflated bills, including the additional 30% cost, are passed on to patients, increasing their overall healthcare expenses. For patients covered by health insurance (which is the case for most MediBuddy app users who are corporate employees), the inflated bills are borne by the insurance company, ultimately resulting in higher premiums for employers providing health coverage to their staff.

The situation becomes even more alarming when we examine the relationship between MediBuddy and Mediassist TPA, the largest insurance third-party administrator (TPA) in the market. Both companies share the same promoters and directors, and they are essentially sister concern companies with identical tech infrastructure. TPAs are bill processing entities regulated by the Insurance Regulatory and Development Authority of India (IRDAI). The regulations governing TPAs explicitly state that promoters of TPAs cannot have conflicting business interests, TPAs cannot charge hospitals for their services, and they cannot demand a share of the payout issued to hospitals.

However, Mediassist TPA seems to be violating these regulations through its association with MediBuddy. This raises concerns about a conflict of interest, as overpaid claims would directly benefit MediBuddy's revenue in this business model. According to a report by the Comptroller and Auditor General of India in 2022, Mediassist has consistently maintained an Incurred Claims Ratio (ICR) above 110% concerning health insurance policies for PSU insurance companies. This suggests financial strain on these PSUs, with the funds potentially being funneled to MediBuddy as part of the 30% kickback deal. Despite these findings, no action has been taken to address the issue.

It is crucial to recognize that this business model is not limited to MediBuddy and Mediassist; other players in the health insurance sector might adopt similar practices. If left unchecked, this trend could lead to a significant surge in healthcare expenses, while hospitals and doctors continue to be blamed for the rising costs. Immediate action and regulatory measures are necessary to address these practices and protect the interests of patients, employers, and insurance companies.

But surprising fact is how can the corporate HR department with eagle eye miss this important money drain?